Shanghai Henlius Biotech (HKG:2696) dosed the first patient in a phase 1 clinical study of HLX48 for injection in Mainland China.
The drug is being tested for the treatment of advanced/metastatic solid tumors, according to a Tuesday Hong Kong bourse filing.